CRESS | $234,000 | (Feb 21, 2025)
Safe Intelligence | $5,253,443 | (Feb 21, 2025)
Reverb Therapeutics | $21,000,000 | (Feb 21, 2025)
Certified by Founder
Lodge
Angitia Biopharmaceuticals
start up
United States
- Woodland Hills, CA
- 12/12/2024
- Series C
- $120,000,000
Angitia is a clinical-stage biotechnology company focused on discovering and developing breakthrough therapeutics that address the key unmet medical needs of serious musculoskeletal diseases. With the team’s experience and scientific expertise in new drug development, Angitia is dedicated to bringing innovative therapeutics to help patients in need.
- Industry Biotechnology Research
- Website https://www.angitiabio.com/
- LinkedIn https://www.linkedin.com/company/angitia-biopharmaceuticals/
Related People
Hua Zhu (David) KeFounder
United States -
Greater Los Angeles, California
Discovery and translational research professional, specifically in bone and renal diseases.
QuSecure | $28,000,000 | (Feb 21, 2025)
AheadComputing | $21,500,000 | (Feb 21, 2025)
Together AI | $30,000,000 | (Feb 21, 2025)
Kodesage | $2,300,000 | (Feb 21, 2025)
OpenEvidence | Undisclosed Amount | (Feb 21, 2025)
Oso Semiconductor | $5,200,000 | (Feb 21, 2025)
EnPlusOne Biosciences | $10,000,000 | (Feb 21, 2025)
Pinkfish | $7,600,000 | (Feb 21, 2025)
Esperto Medical | Undisclosed Amount | (Feb 21, 2025)